What Researchers Did
Researchers reviewed existing studies and clinical evidence on using hyperbaric oxygen therapy as a temporary treatment for severe anaemia when blood transfusions are not an option.
What They Found
Hyperbaric oxygen therapy (HBOT) administered at 2 to 3 ATA can dissolve enough oxygen in plasma to compensate for low haemoglobin levels, which are considered inadequate below 3.6 g/dL. Animal studies from 1943 to the 1990s consistently showed better survival rates in groups treated with HBOT for hemorrhagic shock. Human case reports, case series, and one controlled trial also support HBOT's effectiveness, noting it has a favorable safety profile and a cost similar to a single unit of packed red blood cells.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The evidence supporting HBOT for severe anaemia primarily comes from animal studies, human case reports, and only one controlled prospective trial, indicating a need for more robust human clinical trials.